Gabapentin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Category: Drugs]] [[Category: Anticonvulsant medication]] | [[Category: Drugs]] [[Category: Anticonvulsant medication]] | ||
'''Gabapentin''' (中文: [[加巴噴丁]])is an anticonvulsant medication used primarily in the treatment of: | '''Gabapentin''' (中文: [[加巴噴丁]]) is an anticonvulsant medication used primarily in the treatment of: | ||
*Focal seizures with or without secondary generalization. | *Focal seizures with or without secondary generalization. | ||
*Neuropathic pain caused caused by diabetic neuropathy, postherpetic neuralgia and central neuropathic pain. | *Neuropathic pain caused caused by diabetic neuropathy, postherpetic neuralgia and central neuropathic pain. | ||
Revision as of 06:35, 7 October 2020
Gabapentin (中文: 加巴噴丁) is an anticonvulsant medication used primarily in the treatment of:
- Focal seizures with or without secondary generalization.
- Neuropathic pain caused caused by diabetic neuropathy, postherpetic neuralgia and central neuropathic pain.
- Migraine prophylaxis
Drug Names
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Gabapentin Capsule 100mg | GABA01 | P1S1S3 |
Pronunciation
Gabapentin 100mg
Gabapentin 300mg
Mechanism of Action
Anticonvulsant medication. It inhibits the alpha 2-delta subunit of voltage-gated calcium channels.
Dosage
| Epilepsy | By mouth: the initial oral dose is 300 mg on day 1, then 300mg twice daily on day 2, then 300mg 3 times daily on day 3. Alternatively, 300 mg three times daily on day 1; then increased according to response in steps of 300 mg every 2 -3 days.
Usual dose: 0.9 – 3.6 g daily in 3 divided doses (Max. 4.8 g daily) Doses in children, for use as adjunctive therapy in children aged 6 years and over, and as monotherapy in those aged 12 years or over. 6-12 years (adjunctive therapy):
|
|---|---|
| Neuropathic Pain | By mouth:
Alternatively, 300 mg 3 times daily on day 1, then increased according to response in steps of 300mg (in 3 divided doses) every 2-3 days up to max. 3.6 g daily. |
| Migraine prophylaxis | By mouth:
|
As with other antiepileptics, withdrawal of gabapentin therapy or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in seizure frequency. Withdrawal symptoms typically emerge within 12 hours to 7 days after stopping gabapentin. Commonly reported symptoms include agitation, confusion, disorientation, upset stomach and sweating. In some cases, patients experienced delirium and withdrawal seizures, which may only respond to the re-administration of gabapentin.
Side Effects
Common side effects include:
- Dizziness, fatigue, drowsiness, ataxia, peripheral edema (swelling of extremities), nystagmus and tremor.
- May produce sexual dysfunction in some patients
Potentially serious side effects include:
- An increased risk of suicide, aggressive behaviour
- Acute renal failure
- Deranged liver function tests, hepatitis, jaundice
Rarely, pancreatitis, Stevens-Johnson syndrome and blood glucose functions in diabetes, dystonia, palpitations, thrombocytopenia and tinnitus have been reported. An antiepileptic hypersensitivity syndrome, comprising fever, rash, myocarditis, or myositis. Overdosage of gabapentin, particularly in combination with other CNS depressants, may result in coma.
Pharmacokinetics
| Oral bioavailability | Gabapentin is absorbed from the intestines by means of an active transport process which is saturable, so the pharmacokinetics of gabapentin are dose-dependent, with diminished bioavailability and delayed peak levels at higher doses.
Food increases the bioavailability by about 10%. |
|---|---|
| Onset of action | Gabapentin at a low dose of 100 mg has a Tmax (time to peak levels) of about 1.7 hours, while the Tmax increases to 3 to 4 hours at higher doses. |
| Metabolism | Gabapentin undergoes little or no metabolism. |
| Elimination half-life | Gabapentin is eliminated renally in the urine.
The elimination half-life has been reported to be about 5 to 7 hours. Gabapentin is distributed into breast milk. |
Drug Management
Monitoring
- Recognize signs of blood, liver, or skin toxicity. Seek immediate medical attention if symptoms such as fever, sore throat, rash, blistering, mouth ulcers, bruising or bleeding develop.
- Patients with heart failure should be weighed regularly to detect fluid retention.
- Patients with pre-existing cardiac conduction disorders should be carefully monitored.
- changes in mood, the development or worsening depression, and/or any thoughts or behaviour of suicide.
Drug interaction
| Drugs given with gabapentin | Potential Effect |
|---|---|
| Antacids (containing Magnesium with aluminium) | Absorption of gabapentin from the gut is reduced by antacids. It is recommended that gabapentin is taken at least 2 hours after any such antacid. |
| Morphine | Morphine reduces the clearance of gabapentin; patients receiving both drugs should be monitored for signs for CNS depression and doses should be reduced accordingly. |
Caution
- Avoid abrupt withdrawal
- Used with caution in patients with renal impairment and in those undergoing haemodialysis
- History of psychotic illness
Renal impairment
Reduced doses are recommended for patients with renal impairment or those undergoing haemodyalysis:
- If creatinine clearance 50 to 79 ml/minute: 600 to 1800 mg daily in 3 divided doses.
- If creatinine clearance 30 to 49 ml/minute: 300 to 900 mg daily in 3 divided doses.
- If creatinine clearance 15 to 29 ml/minute: 300 mg on alternate days to 600 mg daily in 3 divided doses.
- If creatinine clearance less than 15 ml/minute: 300 mg on alternate days to 300 mg daily in 3 divided doses.
For those undergoing haemodialysis: the recommended loading dose is 300 mg to 400 mg followed by 200 to 300 mg after each 4 hours of haemodialysis. On dialysis-free days no doses of gabapentin should be given.
Pregnancy
Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)
Breast-feeding
Use during breast feeding is not recommended.
Epilepsy and driving
Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.
FAQ
How should I take the tablet?
Take preferably with or after food.
What should I avoid while taking?
Avoid abruptly discontinue the medication.
What happen if I overdose?
Contact your primary care doctor. If emergency situation, call 999
What happen if I miss a dose?
Take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
